A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

April 29, 2020

Primary Completion Date

July 3, 2020

Study Completion Date

August 3, 2020

Conditions
COVID-19
Interventions
DRUG

Levilimab

Levilimab 324 mg

DRUG

Placebo

Placebo

Trial Locations (16)

Unknown

"State Budgetary Healthcare Institution Kaluga region Kaluga Regional Clinical Hospital", Kaluga

"State Budget Institution of the Republic of Dagestan Republican Clinical Hospital", Makhachkala

A.N. Bakulev National Medical Research Center of Cardiovascular Surgery, Moscow

City Clinical Hospital No. 40 of the Department of Health of the city of Moscow, Moscow

City Clinical Hospital No.52, Moscow

City Clinical Hospital № 15 named. O.M. Filatov, Moscow

City Clinical Hospital №1 named after N.I. Pirogov, Moscow City Health Department, Moscow

"Federal State Budgetary Institution Central Clinical Hospital with Clinic, Office of the President of the Russian Federation", Moscow

I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow

Pirogov Russian National Research Medical University, Moscow

Railway clinical hospital named after N.A. Semashko, Moscow

Almazov National Medical Research Centre, Saint Petersburg

Clinical Infectious Disease Hospital named after S.P. Botkin, Saint Petersburg

North-western State Medical University named after I.I.Mechnikov, Saint Petersburg

"Federal State Budgetary Educational Institution of Higher Education Bashkir State Medical University of the Ministry of Healthcare of the Russian Federation", Ufa

"Federal State Budgetary Educational Institution of Higher Education North Ossetian State Medical Academy of the Ministry of Health of the Russian Federation (FSBEI HE SOGMA of the Ministry of Health of Russia)", Vladikavkaz

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biocad

INDUSTRY

NCT04397562 - A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19 | Biotech Hunter | Biotech Hunter